$NURO
NeuroMetrix, Inc.

2017 Form 10-K Financial Statement

#000162828018001282 Filed on February 08, 2018

View on sec.gov

Income Statement

Concept 2017 2016 Q4 2016
Revenue $17.09M $3.720M $12.03M
YoY Change 42.11% 35.77% 64.76%
Cost Of Revenue $10.24M $2.030M $7.113M
YoY Change 43.9% 26.87% 80.04%
Gross Profit $6.857M $1.690M $4.915M
YoY Change 39.52% 48.25% 46.74%
Gross Profit Margin 40.12% 45.43% 40.86%
Selling, General & Admin $16.44M $3.650M $15.73M
YoY Change 4.54% 7.67% 23.55%
% of Gross Profit 239.79% 215.98% 320.03%
Research & Development $3.498M $910.0K $4.394M
YoY Change -20.41% -14.95% 12.83%
% of Gross Profit 51.01% 53.85% 89.42%
Depreciation & Amortization $262.3K $60.00K $251.3K
YoY Change 4.38% 0.0% 12.91%
% of Gross Profit 3.83% 3.55% 5.11%
Operating Expenses $19.94M $4.550M $20.12M
YoY Change -0.91% 2.02% 21.04%
Operating Profit -$13.08M -$2.860M -$15.21M
YoY Change -13.98% -13.86% 14.55%
Interest Expense $220.0K $50.00K $290.0K
YoY Change -24.14% -91.8% -92.91%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$12.86M -$2.810M -$14.91M
YoY Change -13.75% 3.69% 62.24%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$12.86M -$2.810M -$14.91M
YoY Change -13.77% 3.69% 62.32%
Net Earnings / Revenue -75.23% -75.54% -123.99%
Basic Earnings Per Share -$11.60
Diluted Earnings Per Share -$11.60 -$40.14M -$248.5M
COMMON SHARES
Basic Shares Outstanding 1.701M shares
Diluted Shares Outstanding 1.701M shares

Balance Sheet

Concept 2017 2016 Q4 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.040M $3.950M $3.950M
YoY Change 2.28% -68.3% -68.3%
Cash & Equivalents $4.040M $3.949M $3.950M
Short-Term Investments
Other Short-Term Assets $2.640M $1.650M $1.650M
YoY Change 60.0% 94.12% 94.12%
Inventory $1.370M $1.252M $1.250M
Prepaid Expenses
Receivables $1.050M $738.7K $740.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.100M $7.587M $7.590M
YoY Change 19.89% -49.91% -50.1%
LONG-TERM ASSETS
Property, Plant & Equipment $440.0K $532.7K $530.0K
YoY Change -16.98% -22.07% -22.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $60.00K $160.0K $160.0K
YoY Change -62.5% -20.0% -20.0%
Total Long-Term Assets $500.0K $697.0K $690.0K
YoY Change -27.54% -21.44% -22.47%
TOTAL ASSETS
Total Short-Term Assets $9.100M $7.587M $7.590M
Total Long-Term Assets $500.0K $697.0K $690.0K
Total Assets $9.600M $8.284M $8.280M
YoY Change 15.94% -48.34% -48.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $730.0K $734.0K $730.0K
YoY Change 0.0% -30.76% -31.13%
Accrued Expenses $3.030M $1.649M $1.960M
YoY Change 54.59% 56.21% 3.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.580M $3.318M $3.320M
YoY Change 37.95% 1.9% 1.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.580M $3.318M $3.320M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $4.580M $3.323M $3.320M
YoY Change 37.95% -6.04% -6.21%
SHAREHOLDERS EQUITY
Retained Earnings -$178.5M
YoY Change 9.12%
Common Stock $84.00
YoY Change -79.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.020M $4.961M $4.960M
YoY Change
Total Liabilities & Shareholders Equity $9.600M $8.284M $8.280M
YoY Change 15.94% -48.55% -48.57%

Cashflow Statement

Concept 2017 2016 Q4 2016
OPERATING ACTIVITIES
Net Income -$12.86M -$2.810M -$14.91M
YoY Change -13.77% 3.69% 62.32%
Depreciation, Depletion And Amortization $262.3K $60.00K $251.3K
YoY Change 4.38% 0.0% 12.91%
Cash From Operating Activities -$12.65M -$3.620M -$15.08M
YoY Change -16.1% 4.02% 15.11%
INVESTING ACTIVITIES
Capital Expenditures $163.1K -$10.00K $100.5K
YoY Change 62.29% -83.1%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$163.1K -$10.00K -$100.0K
YoY Change 63.1% -83.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $12.91M 20.00K 6.670M
YoY Change 93.55% -99.71% -60.63%
NET CHANGE
Cash From Operating Activities -$12.65M -3.620M -15.08M
Cash From Investing Activities -$163.1K -10.00K -100.0K
Cash From Financing Activities $12.91M 20.00K 6.670M
Net Change In Cash $94.55K -3.610M -8.510M
YoY Change -101.11% -207.76% -361.85%
FREE CASH FLOW
Cash From Operating Activities -$12.65M -$3.620M -$15.08M
Capital Expenditures $163.1K -$10.00K $100.5K
Free Cash Flow -$12.82M -$3.610M -$15.18M
YoY Change -15.58% 3.74% 10.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
19846377 USD
CY2017 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
6874780 USD
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Document Type
DocumentType
10-K
CY2016 nuro Sales Revenue Goods Net Percentage From Foreign Country
SalesRevenueGoodsNetPercentageFromForeignCountry
0.12
CY2017 nuro Fair Value Adjustmentof Warrants Repricing
FairValueAdjustmentofWarrantsRepricing
244611 USD
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001289850
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7141940 shares
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q2 dei Entity Public Float
EntityPublicFloat
4309853 USD
CY2017 dei Entity Registrant Name
EntityRegistrantName
NeuroMetrix, Inc.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Trading Symbol
TradingSymbol
NURO
CY2016Q4 nuro Accrued Sales Return Allowance Current
AccruedSalesReturnAllowanceCurrent
488200 USD
CY2017Q4 nuro Accrued Sales Return Allowance Current
AccruedSalesReturnAllowanceCurrent
666375 USD
CY2016Q4 nuro Accrued Sales Return Provisions
AccruedSalesReturnProvisions
488200 USD
CY2017Q4 nuro Accrued Sales Return Provisions
AccruedSalesReturnProvisions
666375 USD
CY2016Q4 nuro Common Stock Warrants
CommonStockWarrants
4641 USD
CY2017Q4 nuro Common Stock Warrants
CommonStockWarrants
0 USD
CY2016Q4 nuro Common Stock Warrants Fair Value Disclosure
CommonStockWarrantsFairValueDisclosure
4641 USD
CY2016 nuro Exchange Of Warrant Liability For Preferred Stock
ExchangeOfWarrantLiabilityForPreferredStock
0 USD
CY2017 nuro Exchange Of Warrant Liability For Preferred Stock
ExchangeOfWarrantLiabilityForPreferredStock
40772 USD
CY2016 nuro Fair Value Adjustmentof Warrants Repricing
FairValueAdjustmentofWarrantsRepricing
0 USD
CY2016 nuro Fixed Asset Additions Included In Accounts Payable
FixedAssetAdditionsIncludedInAccountsPayable
0 USD
CY2017 nuro Fixed Asset Additions Included In Accounts Payable
FixedAssetAdditionsIncludedInAccountsPayable
7374 USD
CY2017Q4 nuro Income Tax Expense Benefit Attributable To Net Operating Loss Carry Forward
IncomeTaxExpenseBenefitAttributableToNetOperatingLossCarryForward
2600000 USD
CY2017Q4 nuro Income Tax Expense Benefit Attributable To Tax Credit Carry Forwards
IncomeTaxExpenseBenefitAttributableToTaxCreditCarryForwards
71238 USD
CY2017Q4 nuro Restricted Cash Collateral Letters Of Credit
RestrictedCashCollateralLettersOfCredit
200000 USD
CY2017 nuro Sales Revenue Goods Net Percentage From Foreign Country
SalesRevenueGoodsNetPercentageFromForeignCountry
0.07
CY2017Q4 nuro Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Price Per Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAveragePricePerShares
19.32
CY2016 nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
318761 USD
CY2017 nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
0 USD
CY2016 nuro Stock Issued During Period Value To Settle Incentive Compensation Obligations
StockIssuedDuringPeriodValueToSettleIncentiveCompensationObligations
318761 USD
CY2016Q4 nuro Technology Fees
TechnologyFees
450000 USD
CY2017Q4 nuro Technology Fees
TechnologyFees
450000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
734048 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
733305 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
738729 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1049329 USD
CY2016Q4 us-gaap Accrued Advertising Current
AccruedAdvertisingCurrent
28100 USD
CY2017Q4 us-gaap Accrued Advertising Current
AccruedAdvertisingCurrent
160800 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1648731 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2242315 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
390800 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
603000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2567510 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1133435 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
183439463 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
196355142 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
225408 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
209691 USD
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
225408 USD
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
836863 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2706066 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2706066 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10147721 shares
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
209691 USD
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
25000 USD
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
25000 USD
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3976895 shares
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8803289 shares
CY2016Q4 us-gaap Assets
Assets
8283891 USD
CY2017Q4 us-gaap Assets
Assets
9599224 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
7586923 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
9103374 USD
CY2017Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
1744965 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12462872 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3949135 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4043681 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4000000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1744965 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8513737 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
94546 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1170717 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
836863 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2706066 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2706066 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1268440 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
84 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
271 USD
CY2016 us-gaap Cost Of Revenue
CostOfRevenue
7113005 USD
CY2017 us-gaap Cost Of Revenue
CostOfRevenue
10235538 USD
CY2016Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
910595 USD
CY2017Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
2106988 USD
CY2016Q4 us-gaap Deferred Revenue And Credits Current
DeferredRevenueAndCreditsCurrent
1247545 USD
CY2017Q4 us-gaap Deferred Revenue And Credits Current
DeferredRevenueAndCreditsCurrent
3010734 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
628236 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
820031 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49274154 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35331314 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45759780 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31902006 USD
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
14321 USD
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
19240 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2180700 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2432058 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
566487 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
229676 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
752866 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
748334 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49300000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49274154 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35300000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35331314 USD
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
CY2016 us-gaap Depreciation
Depreciation
251327 USD
CY2017 us-gaap Depreciation
Depreciation
262334 USD
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
251327 USD
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
262334 USD
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-58.21
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.60
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.393
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1.096
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
1.503
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.042
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.059
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.009
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.007
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
307471 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
786184 USD
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
335405 USD
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M0D
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-275662 USD
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-208480 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4872670 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5689917 USD
CY2016 us-gaap Gross Profit
GrossProfit
4914523 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
754797 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
884642 USD
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
630361 USD
CY2017 us-gaap Gross Profit
GrossProfit
6856798 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-267583 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8117 USD
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-69096 USD
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
310600 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
347176 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1072297 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
401064 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
191795 USD
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
163154 USD
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
117409 USD
CY2016 us-gaap Interest And Other Income
InterestAndOtherIncome
19132 USD
CY2017 us-gaap Interest And Other Income
InterestAndOtherIncome
14885 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-163096 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15080276 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12652384 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-13082618 USD
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
864354 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
1252238 USD
CY2017Q4 us-gaap Inventory Net
InventoryNet
1369647 USD
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
466906 USD
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
505293 USD
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
154971 USD
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 USD
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
581928 USD
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
670860 USD
CY2016Q4 us-gaap Liabilities
Liabilities
3323127 USD
CY2017Q4 us-gaap Liabilities
Liabilities
4581835 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8283891 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9599224 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3318486 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4581835 USD
CY2017 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2019-01-15
CY2017Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
2500000 USD
CY2017Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
2300000 USD
CY2016 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
6311000 USD
CY2017 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
6851000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6667038 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12910026 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-100499 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-14913151 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-12859253 USD
CY2016 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-34759528 USD
CY2017 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19734033 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
20122468 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
19939416 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-15207945 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2167173 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
573421 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
81562 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
487379 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
475408 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
549403 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
245752 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
234779 USD
CY2016Q4 us-gaap Other Deferred Credits Current
OtherDeferredCreditsCurrent
619309 USD
CY2017Q4 us-gaap Other Deferred Credits Current
OtherDeferredCreditsCurrent
2190703 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
100499 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
163096 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
164262 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
55008 USD
CY2016 us-gaap Proceeds From Repurchase Of Equity
ProceedsFromRepurchaseOfEquity
6667038 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1646821 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2640717 USD
CY2017 us-gaap Proceeds From Repurchase Of Equity
ProceedsFromRepurchaseOfEquity
12910026 USD
CY2016Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
45879 USD
CY2017Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
127361 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3100216 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1574277 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
532706 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
440842 USD
CY2017Q4 us-gaap Purchase Obligation
PurchaseObligation
4218229 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4394353 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3497636 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178478801 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-191300000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-191338054 USD
CY2016 us-gaap Revenues
Revenues
12027528 USD
CY2017 us-gaap Revenues
Revenues
17092336 USD
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10855445 USD
CY2017 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10751863 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
225408 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
209691 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.700
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.700
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
25388 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
37.26
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
17 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
23825 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6488 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.80
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.37
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
97891 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
80537 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
37.95
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.32
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
80537 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
19.32
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
11187.28
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
83.27
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.37
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
80537 shares
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2016Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
45879 USD
CY2017Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
127361 USD
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2017 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
0 USD
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
28538 USD
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
20768 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
12562708 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
4960764 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
5017389 USD
CY2017Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.125
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
597130 shares
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1701481 shares
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents in bank deposit accounts and trade receivables. The Company invests its funds in highly rated institutions and limits its investment in any individual account so that they do not exceed FDIC limits. The Company has not experienced significant losses related to cash and cash equivalents and does not believe it is exposed to any significant credit risks relating to its cash and cash equivalents.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, two customers accounted for </font><font style="font-family:inherit;font-size:10pt;">66%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">41%</font><font style="font-family:inherit;font-size:10pt;"> of accounts receivable, respectively. For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, customers accounting for more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of revenue were </font><font style="font-family:inherit;font-size:10pt;">19%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> of revenues, respectively. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company relies on in-house assembly and four third-party manufacturers to manufacture the major portion of its current products and product components. The disruption or termination of the supply of these products or a significant increase in the cost of these products from these sources could have an adverse effect on the Company&#8217;s business, financial position, and results of operations.</font></div></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates and Assumptions</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances and regularly assesses these estimates, but actual results could differ materially from these estimates. Effects of changes in estimates are recorded in the period in which they occur.</font></div></div>

Files In Submission

Name View Source Status
0001628280-18-001282-index-headers.html Edgar Link pending
0001628280-18-001282-index.html Edgar Link pending
0001628280-18-001282.txt Edgar Link pending
0001628280-18-001282-xbrl.zip Edgar Link pending
a10k2017ex1019-apa.htm Edgar Link pending
a10k2017ex1020-devser.htm Edgar Link pending
a10k2017ex1021-contribution.htm Edgar Link pending
a10k2017ex1022-quellipcorp.htm Edgar Link pending
a10k2017ex1023-spvlicenset.htm Edgar Link pending
a10k2017ex1024-spvlicenset.htm Edgar Link pending
a10k2017ex1025-assign.htm Edgar Link pending
a10k2017ex1027.htm Edgar Link pending
a10k2017ex231.htm Edgar Link pending
a10k2017ex232.htm Edgar Link pending
a10k2017ex4211.htm Edgar Link pending
a10k2017exhibit311.htm Edgar Link pending
a10k2017exhibit312.htm Edgar Link pending
a10k2017exhibit32.htm Edgar Link pending
a10knuro20171231.htm Edgar Link pending
ex1027sig.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nuro-20171231.xml Edgar Link completed
nuro-20171231.xsd Edgar Link pending
nuro-20171231_cal.xml Edgar Link unprocessable
nuro-20171231_def.xml Edgar Link unprocessable
nuro-20171231_lab.xml Edgar Link unprocessable
nuro-20171231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending